Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Preferred Dividend Payments (2021 - 2025)

Ani Pharmaceuticals' Preferred Dividend Payments history spans 7 years, with the latest figure at $344000.0 for Q3 2025.

  • On a quarterly basis, Preferred Dividend Payments fell 15.27% to $344000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 28.8% decrease, with the full-year FY2025 number at $1.2 million, down 28.8% from a year prior.
  • Preferred Dividend Payments hit $344000.0 in Q3 2025 for Ani Pharmaceuticals, down from $407000.0 in the prior quarter.
  • Over the last five years, Preferred Dividend Payments for ANIP hit a ceiling of $407000.0 in Q2 2022 and a floor of $190000.0 in Q4 2021.
  • Historically, Preferred Dividend Payments has averaged $388875.0 across 5 years, with a median of $406000.0 in 2022.
  • Biggest five-year swings in Preferred Dividend Payments: skyrocketed 114.21% in 2022 and later dropped 15.27% in 2025.
  • Tracing ANIP's Preferred Dividend Payments over 5 years: stood at $190000.0 in 2021, then surged by 114.21% to $407000.0 in 2022, then fell by 0.25% to $406000.0 in 2023, then changed by 0.0% to $406000.0 in 2024, then decreased by 15.27% to $344000.0 in 2025.
  • Business Quant data shows Preferred Dividend Payments for ANIP at $344000.0 in Q3 2025, $407000.0 in Q2 2025, and $406000.0 in Q1 2025.